The Hinduja-supported MindMaze has secured a $105 million financing round to accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases. 

The financing round provides immediate access to funds and a financing facility to fund growth and future acquisitions. The financing was led by Concord Health Partners, a US-based healthcare private equity firm focusing on investing in and supporting healthcare companies with innovative technologies and solutions that address quality, cost and access to care along with other investors. 

AlbaCore Capital Group, one of Europe’s leading specialist investors focusing on public and private markets, are building on their existing investment as a reflection of their continued commitment to the company. 

This round also included participation from London-based Hambro Perks, an investor with deep expertise in the sector and a global portfolio of disruptive, highly scalable companies, and several family office investment groups. Furthermore, as a result of Concord’s investment, MindMaze will initiate a partnership with The American Hospital Association (AHA).